TY - JOUR
AR - IJRGM-2022-2-102
TI - Hematopoietic Stem Cell Transplantation in Juvenile Myelomonocytic Leukemia: A Case Report and Literature Review
AU - Malek, Benakli
AU - Redhouane, Ahmed Nacer
AU - Farih, Mehdid
AU - Mounira, Baazizi
AU - Nadia, Rahmoune
AU - Dina, Ait Ouali
AU - Hanane, Bouarab
AU - Sara, Zerkout
AU - Fouzia, Louar
AU - Rose, Marie Hamladji
JO - International Journal of Regenerative Medicine
PY - 2022
DA - Fri 14, Oct 2022
SN - 2613-5914
DO - http://dx.doi.org/10.31487/j.RGM.2022.02.02
UR - https://www.sciencerepository.org/hematopoietic-stem-cell-transplantation_RGM-2022-2-102 
KW - Juvenile myelomonocytic leukemia, myelodysplastic/myeloproliferative diseases, pediatric leukemia, allogeneic hematopoietic stem cell transplantation
AB - Juvenile myelomonocytic leukemia (JMML) is a rare hematological malignancy of early childhood, classified by the World Health Organization as a myelodysplastic/myeloproliferative disease and is associated with a poor prognosis. Allogeneic hematopoietic stem cell transplantation is the only curative treatment. A two-year-old male child was diagnosed with JMML and was given induction chemotherapy. One year after diagnosis, the patient received allogeneic hematopoietic stem cell transplantation from an HLA sibling donor after a myeloablative conditioning regimen. The patient remained free of disease after 5 years of follow-up, healthy, with complete clinical, immunologic and hematologic recovery, without signs of JMML. Transplantation is the only modality to achieve a cure in JMML patients. The most widely practiced approach is the use of bone marrow or peripheral blood stem cells after a myeloablative conditioning regimen. Post-transplant monitoring chimerism can help identify the patients who are at risk of relapse.